Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
HEALTHCARE - CHEMICALS IN PLASTICS

Chemicals in plastics pose danger

 

BY OUR PHARMA  CORRESPONDENT

11 August, 2005: Recent scientific evidences suggests that certain chemicals like phthalates and Bisphenol A (BPA) designed to soften plastics could cause potential harm.

Increasing number of research data indicate that these bioactive chemicals are dangerous and should be banned.

Nevertheless, the chemical industry insists that phthalates and BPA are harmless. American Plastics Council sources maintain that the potential human exposure to BPA is extremely low and poses no known risk to human health, citing safety assessments from European and US regulatory agencies.

While some others argue that European and US assessments are based on scientific literature published in the 1980s and 1990s. There are now over a hundred [recent] studies showing adverse affects of BPA in different animal models, they say. The tests performed on rodents cannot be extrapolated to indicate potential human health effects.

Regulatory agencies attempt to apply a substantial safety factor when extrapolating from animal models to the human situation. For example, the US Environmental Protection Agency (EPA) calculated the acceptable daily intake level (known as the Reference Dose, or RfD) for BPA by dividing the rodent "lowest effect" level of 50,000 µg/kg/day by 1000 to obtain an RfD of 50 µg/kg/day. The European Commission adopted a more conservative acceptable daily intake level of 10 µg/kg/day.

However, many recent studies have highlighted potential harmful effects of very low doses of phthalates and estrogenic compounds. These studies raise questions as to the actual human exposure levels. In the case of pregnant women, as BPA may be concentrated in the human placenta and amniotic fluid as fetal development represents the most sensitive period of life in terms of exposure to chemicals like phthalates and BPA.

Earlier, reproductive biologists from the University of South Dakota investigated the effects of estrogenic compounds on pregnant mice. They had found that fluctuations in the levels of the natural endogenous hormone estradiol induced changes in prostate development in utero.

In their study, they fed low levels of BPA (10 µg/kg/day) to pregnant mice for four days.1They then removed fetuses by cesarean section and removed the prostates from male embryos. Using sophisticated 3-D image reconstruction, they made precise measurements of the developing prostate. As a positive control, they group used diethylstilbestrol (DES), an estrogenic compound similar in structure to BPA and associated with reproductive organ defects and cancer in humans.

They noted that low-level exposure to the compounds caused an increase (up to 40%) in the size and the number of the prostate ducts, and increases in proliferation of the basal epithelial cells of the primary ducts. They also observed a narrowing of the bladder neck and urethra. The researchers suggest that the observed deformities could predispose animals to prostate cancer and bladder disease in later life, and that the virtually identical effects of BPA and DES make a strong case for the relevance of the rodent model and the potential human hazards.

Recently, the Tufts University Medical School in Boston researchers showed that environmentally relevant doses of BPA affect mammary gland development in mice and the University of Rochester School of Medicine and Dentistry, New York, reported an association between male genital defects and phthalate exposure in pregnant women. Also, in collaboration with researchers at Yale University they found evidence for BPA effects on brain development in rodents.

Still, researchers are divided over the study's relevance to human health.

BY OUR PHARMA  CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us